Clinical Trial Update: Abiraterone Acetate in Combination With Tildrakizumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating abiraterone acetate in combination with tildrakizumab for metastatic castration-resistant prostate cancer has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED